摘要: |
[目的] 通过检测系统性红斑狼疮(SLE)患者血清中白细胞介素-6(IL-6)、白细胞介素-8(IL-8)的水平,探讨二者与SLE疾病活动性的关系及临床价值。[方法] 将71例SLE患者按病情活动与否分为活动与非活动两组,采用ELISA方法检测两组及健康对照组血清IL-6、IL-8水平。[结果]SLE患者血清IL-6、IL-8含量分别为(97.3±41.3)、(104.4±48.7)pg/mlL, 显著高于健康对照组的(37.5±8.4)、(31.5±10.5)pg/mL,二者差异具有显著性意义(P<0.01);SLE活动组患者血清IL-6、IL-8含量分别为(108.4±43.2 )、(113.5±46.2 )pg/mL,明显高于非活动组的(71.3±38.7)、(77.4±41.3)pg/mL,二者亦差异具有显著性意义(P<0.01)。并且与SLE活动性呈正相关(r=0.942;r=0.936)。[结论]SLE患者体内免疫系统功能紊乱、功能异常,造成细胞因子IL-6、IL-8表达异常增高。监测患者血清IL-6、IL-8水平,对了解SLE患者病情活动情况、指导临床治疗及观察疗效、判断预后具有一定的临床应用价值。 |
关键词: 系统性红斑狼疮 IL-6 IL-8 |
DOI:10.11724/jdmu.2007.05.27 |
分类号: |
基金项目: |
|
Changes in serum level of IL-6,IL-8 in active patiets with systemic lupus erythematosus and its clinic value |
MA Yue1, LI Xiao-lan1, DU Gui-zhen2, XU Guo-li3
|
1.Department of Clinical Laboratory, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027,China;2.Department of Clinical Laboratory,the Lingyuan No.1 People's Hospital,Lingyuan 122500,China;3.Department of Clinical Laboratory,the Affiliated Zhongshan Hospital of Dalian University,Dalian 116001,China
|
Abstract: |
[Objective]To evaluate the relationship between level of IL-6,IL-8 in sera and the activity of systemic lupus erythematosus(SLE).[Methods]We divided 71 cases with active SLE into two groups (active SLE, non-active SLE), serum level of IL-6, IL-8 were measured by ELISA method.[Results]The serum level of IL-6,IL-8 in SLE patients were respectively(97.3±41.3)pg/mL and (104.4±48.7)pg/ml,significantly higher than normal control:(37.5±8.4)pg/mL and (31.5±10.5)pg/mL (P<0.01) .Furthermore, the serum level of IL-6,IL-8 (108.4±43.2) and (113.5±46.2)pg/mL from active SLE patients were evidently higher than those (71.3±38.7) and (77.4±41.3 )pg/mL, from non-active SLE (P<0.01). The serum level of cytokines had a positive correlation with the activity of SLE.(r=0.942; r=0.936).[Conclusions]Immunilogical system's function disturbance and abnormality in SLE cause the abnormal increase of cytokines. Supervision of serum cytokines has important clinical value in understanding activity of SLE, instructing clinical therapy, observation of therapy effect and judging the prognosis. |
Key words: systemic lupus ertyematosus interleukin-6 interleukin-8 |